Sentences with phrase «synuclein in»

BHB inhibited the accumulation of the protein alpha - synuclein in NL5901 nematodes.

Propagation and aggregation of alpha synuclein in murine models K. R. WALKER, W. ARIAS, J. BERGER, N. CHIRICHELLA, B. S. NUNEZ, R. SPRINGER, K. CIRILLO, J. SANCHEZ - PADILA, G. TOMBAUGH, A. GHAVAMI, S. RAMBOZ... Abstract / Posters

Propagation and aggregation of alpha synuclein in murine models S RAMBOZ WASHINGTON A, RAYNEL S, JASON B, NICOLE C, SHEILYN N, KIMBERLY C, KIM C, KENDALL W... Abstract / Posters

The animal model used for this study, C. elegans, is a nematode worm genetically engineered to produce human α - synuclein in its muscles.

α - synuclein in Saccharomyces cerevisiae: model for aggregate clearance, cell survival and influence of autophagy.

C - Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α - Synuclein in a Yeast Model of Parkinson's Disease.

As the first research team worldwide, they succeeded in demonstrating — and visualising — α - synuclein in neuronal and non-neuronal cells.

- synuclein in living, healthy cells: The central NAC region (grey) is well protected.

One of the trademarks of Parkinson's Disease, for example, is an excess of alpha - synuclein in the brain.

Apparently, too much alpha - synuclein in the nerve terminal causes microtubules to over-assemble and somehow get in the way of endocytosis.

With the help of a tailor - made viral vector they triggered production of human alpha - synuclein in rats.

Since then, scientists have come to appreciate that many proteins associated with neurodegenerative diseases — including amyloid - β and tau in Alzheimer's disease and α - synuclein in Parkinson's disease — misfold catastrophically.

The Penn team also found that patients with this genetic variation had a slower rate of Parkinson's disease progression, and lower amounts of alpha - synuclein in the brain.

Arising from the abnormal buildup of a protein known as alpha - synuclein in the brain, such conditions damage the nerves that control blood pressure and heart rate.

Different proteins are implicated in each disease: tau in Alzheimer's, alpha - synuclein in Parkinson's and huntingtin in Huntington's disease.

Not exact matches

This drug is designed to reduce the build up of a neural protein in the brain called alpha - synuclein that is associated with the disease.

For example, in sporadic PD, multiple GWAS point to the alpha - synuclein gene (SNCA) as one of the strongest risk loci in patients» genomes, yet GWAS contain little information regarding the mechanism of how this gene is dysregulated in sporadic PD patients.

When compared to the enhanced alpha - synuclein production in the familial form of the disease, the modest effect created by the A to G mutation would be sufficient over a lifetime to increase the risk of PD, according to Soldner.

The researchers deployed this technology in yeast cells that are genetically engineered to overproduce a protein associated with Parkinson's disease, known as alpha - synuclein.

The researchers hypothesize that these chaperone proteins may assist in the proper folding of alpha synuclein, which could prevent it from forming clumps.

That leads the protein alpha - synuclein to build up and form toxic clumps in brain areas that control motor function.

The study, published in the October edition of the journal Neurotherapeutics, found that the drug, AT2101, which has also been studied for Gaucher disease, improved motor function, stopped inflammation in the brain and reduced levels of alpha - synuclein, a protein critically involved in Parkinson's.

With the new technology, the scientists hope to identifying ways to reduce alpha - synuclein production that can possibly prevent Parkinson's or its progression in patients diagnosed with the disease.

In the quest for an animal model of PD that mimics motor and non-motor symptoms of human PD, scientists have developed strains of mice that overexpress α - synuclein.

With the engineered cells, researchers can screen new and existing drugs to see how they regulate alpha - synuclein level in patients.

The technology allows scientists in the lab to «light up» and then monitor a brain protein called alpha - synuclein that has been associated with Parkinson's.

By studying a strain of mice bred to overexpress α - synuclein via the Thy - 1 promoter, scientists have found these mice develop many of the age - related progressive motor symptoms of PD and demonstrate changes in sleep and anxiety.

«Alpha - synuclein is a protein that is normally found in the brain.

Other rodent models that utilize changes in expression of α - synuclein have also reported lower anxiety levels.

«Parkinson's disease - like sleep and motor problems observed in alpha - synuclein mutant mice.»

Whether in a yeast cell or in a neuron, alpha synuclein directly interfered with the rate of production of proteins in the cell, and the transport of proteins between cellular compartments.

«In the second paper, we created a spatial map of alpha - synuclein, cataloging all the proteins in living neurons that were in close proximity to the protein,» explained Chee Yeun Chung, former Whitehead Institute Senior Research Scientist, who co-led both studies with KhuranIn the second paper, we created a spatial map of alpha - synuclein, cataloging all the proteins in living neurons that were in close proximity to the protein,» explained Chee Yeun Chung, former Whitehead Institute Senior Research Scientist, who co-led both studies with Khuranin living neurons that were in close proximity to the protein,» explained Chee Yeun Chung, former Whitehead Institute Senior Research Scientist, who co-led both studies with Khuranin close proximity to the protein,» explained Chee Yeun Chung, former Whitehead Institute Senior Research Scientist, who co-led both studies with Khurana.

The disease is caused by the accumulation of abnormally shaped α - synuclein proteins in neurons, leading to particularly toxic effects in dopamine - releasing cells located in brain regions that control movement.

(To do the experiment in a blinded, unbiased manner, the Loyola researchers did not know which types of alpha - synuclein were which.)

If it emerges that it is indeed a «catcher's mitt» for α - synuclein, it could provide a drug target for a disease whose 10 million sufferers are sorely in need of new medicines.

«Activation of these cell receptors appear to prevent brain cells from cleaning out the trash — the toxic buildup of proteins, such as alpha - synuclein, tau and amyloid, common in neurodegenerative diseases,» says the study's senior author, neurologist Charbel Moussa, MBBS, PhD, director of Georgetown's Laboratory for Dementia and Parkinsonism, and scientific and clinical research director of the GUMC Translational Neurotherapeutics Program.

«With Diego's discovery, we've made a direct connection between the protein α - synuclein and the downstream effects that are observed when brain cells become damaged in Parkinson's.»

In the current study, Lasmézas and her team looked at cell cultures of neurons that were induced to accumulate fibrils made of misfolded α - synuclein, mimicking Lewy bodies in patients with Parkinson'In the current study, Lasmézas and her team looked at cell cultures of neurons that were induced to accumulate fibrils made of misfolded α - synuclein, mimicking Lewy bodies in patients with Parkinson'in patients with Parkinson's.

He and his colleagues, including first author, Tessandra Stewart, PhD, suggest that the decrease in CSF α - synuclein may be the result of a compensatory process, reflecting greater retention of the protein in the brain.

Researchers at the University of Pittsburgh School of Medicine have uncovered a major reason why the Parkinson's - related protein alpha - synuclein, a major constituent of the Lewy bodies that are the pathological hallmark of Parkinson's disease (PD), is toxic to neurons in the brain.

They found that by attaching to a mitochondrial protein called TOM20, alpha - synuclein prevented the mitochondria from functioning optimally, which resulted in the production of less energy and more damaging cellular waste.

In the new study, Dr. Greenamyre and his team — led by coauthors Roberto Di Maio, Ph.D., and Paul Barrett, Ph.D., both of PIND — used a well - established rodent model of PD to show exactly how alpha - synuclein disrupts mitochondrial function.

Data from 304 PD patients followed for up to 8 years indicate that patients with higher cerebrospinal fluid (CSF) α - synuclein levels experienced faster cognitive decline in the following months, although no associations were found between α - synuclein levels and motor changes.

In mice infected with the H5N1 virus, deposits of phosphorylated alpha - synuclein (arrows) in dopamine neurons may be a sign of neurodegeneratioIn mice infected with the H5N1 virus, deposits of phosphorylated alpha - synuclein (arrows) in dopamine neurons may be a sign of neurodegeneratioin dopamine neurons may be a sign of neurodegeneration.

Although several large studies have shown that α - synuclein levels are lower in the CSF of PD patients and those with related synucleinopathies compared to controls, its role in cognitive decline and dementia had been unexplored.

Yet if you look at people who develop the clinical syndrome of dementia, especially later in life, yes, they have amyloid in the brain but they also have other pathologic entities — vascular disease; synucleinopathies [insoluble fibrils of the normally soluble protein, alpha - synuclein]; a tauopathy [which is marked by disease - inducing, insoluble tangles of another protein, tau].

Because most cases of Parkinson's disease appear to be at least partially caused by environmental factors such as pesticide exposure, these findings support the approach that targeting α - synuclein could slow or stop the progression of Parkinson's in most people with the disease, said study lead author Jeff Bronstein, a professor of neurology and director of movement disorders at the David Geffen School of Medicine at UCLA.

In the new study, conducted in zebrafish, researchers found that elimination of the α - synuclein protein protected the zebrafish against the ziram - induced loss of dopamine neuronIn the new study, conducted in zebrafish, researchers found that elimination of the α - synuclein protein protected the zebrafish against the ziram - induced loss of dopamine neuronin zebrafish, researchers found that elimination of the α - synuclein protein protected the zebrafish against the ziram - induced loss of dopamine neurons.

The pathological hallmark of this disease is the accumulation of alpha - synuclein, which in turn leads to cell death and consequently to problems in neurotransmission.

The pesticide - linked damage starts with ziram's ability to increase concentrations of a protein, called α - synuclein, which is abundant in the human brain.